The Taiwan Food and Drug Administration approved Hemlibra from Chugai Pharmaceutical to prevent bleeding episodes in patients with hemophilia A with factor VIII inhibitors. Regulators based their approval on two studies.
Taiwan OKs Chugai's Hemlibra to treat hemophilia A with inhibitors
Sign up for AABB SmartBrief
News about transfusion and cellular therapies
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.